Literature DB >> 16441456

Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.

H Wisplinghoff1, H Seifert, R P Wenzel, M B Edmond.   

Abstract

Candida spp. are an important cause of nosocomial bloodstream infection (nBSI) and are associated with significant morbidity and mortality. An historical cohort study was performed to evaluate the clinical course of 60 randomly selected adult patients with nBSIs caused by Candida spp. Patients with BSI caused by Candida albicans (n = 38) and non-albicans spp. (n = 22) were compared with 80 patients with Staphylococcus aureus BSI by serial systemic inflammatory response syndrome (SIRS) and APACHE II scores. The patients had a mean age of 52 years, the length of hospital stay before BSI averaged 21 days, and 57% of patients required care in an intensive care unit before BSI. The mean APACHE II score was 17 on the day of BSI, and 63% of BSIs were caused by C. albicans. Antifungal therapy within the first 24 h of onset of BSI was appropriate in 52% of patients. Septic shock occurred in 27% of patients, and severe sepsis in an additional 8%. Overall mortality was 42%, and the 7-day mortality rate was 27%. The inflammatory response and clinical course were similar for patients with BSI caused by C. albicans and non-albicans spp. In univariate analysis, progression to septic shock was correlated with high overall mortality, as was an APACHE II score >25 at the onset of BSI. In multivariate analysis, the APACHE II score at the onset of BSI and a systemic inflammatory response independently predicted overall mortality, but the 7-day mortality rate was only predicted independently by the APACHE II score. Clinical course and mortality in patients with Candida BSI were predicted by systemic inflammatory response and APACHE II score, but not by the infecting species.

Entities:  

Mesh:

Year:  2006        PMID: 16441456     DOI: 10.1111/j.1469-0691.2005.01318.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  22 in total

Review 1.  [Therapeutic or prophylactic antifungal vaccination: problems and solutions].

Authors:  S Boneberger; H C Korting
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

2.  Creation and assessment of a clinical predictive model for candidaemia in patients with candiduria.

Authors:  Katie Wang; Kevin Hsueh; Ryan Kronen; Charlotte Lin; Ana S Salazar; William G Powderly; Andrej Spec
Journal:  Mycoses       Date:  2019-05-22       Impact factor: 4.377

3.  Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.

Authors:  Laura Bedin Denardi; Jéssica Tairine Keller; Vanessa Oliveira; Débora Alves Nunes Mario; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2017-05-10       Impact factor: 2.574

Review 4.  Can host receptors for fungi be targeted for treatment of fungal infections?

Authors:  Scott G Filler
Journal:  Trends Microbiol       Date:  2013-06-21       Impact factor: 17.079

5.  A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality.

Authors:  Matteo Bassetti; Elda Righi; Filippo Ansaldi; Maria Merelli; Cecilia Trucchi; Trucchi Cecilia; Gennaro De Pascale; Ana Diaz-Martin; Roberto Luzzati; Chiara Rosin; Leonel Lagunes; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Giorgio Della Rocca; Massimo Antonelli; Mario Tumbarello
Journal:  Intensive Care Med       Date:  2014-05-08       Impact factor: 17.440

6.  In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis.

Authors:  Mahipal G Sinnollareddy; Michael S Roberts; Jeffrey Lipman; Melissa Lassig-Smith; Therese Starr; Thomas Robertson; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

7.  Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.

Authors:  V Nagappan; D Boikov; J A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

8.  Nonparametric estimation of broad sense agreement between ordinal and censored continuous outcomes.

Authors:  Tian Dai; Ying Guo; Limin Peng; Amita Manatunga
Journal:  Stat Med       Date:  2020-03-23       Impact factor: 2.373

Review 9.  Candida glabrata: a review of its features and resistance.

Authors:  C F Rodrigues; S Silva; M Henriques
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-19       Impact factor: 3.267

Review 10.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?

Authors:  Vasiliki Soulountsi; Theodoros Schizodimos; Serafeim Chrysovalantis Kotoulas
Journal:  Infection       Date:  2021-06-16       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.